NTLA - Intellia Therapeutics, Inc.
13.44
0.290 2.158%
Share volume: 3,311,227
Last Updated: 03-06-2026
Pharmaceutical Products/In Vitro, In Vivo Diagnostic Substances:
-0.04%
PREVIOUS CLOSE
CHG
CHG%
$13.15
0.29
0.02%
View ratios
| Fiscal Date | 03-31-2024 | 06-30-2024 | 09-30-2024 | 12-31-2024 | 03-31-2025 | 06-30-2025 | 09-30-2025 | 12-31-2025 | |
|---|---|---|---|---|---|---|---|---|---|
| Fiscal Quarter | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
| Report Date | 05-09-2024 | 08-08-2024 | 11-07-2024 | 02-27-2025 | 05-08-2025 | 08-07-2025 | 11-06-2025 | 02-26-2026 | |
| Assets | |||||||||
| Total Assets | 1.260 B | 1.192 B | 1.173 B | 1.191 B | 986.163 M | 898.894 M | 925.275 M | 842.127 M | |
| Current Assets | 884.043 M | 757.211 M | 710.902 M | 639.863 M | 551.392 M | 495.945 M | 581.941 M | 527.711 M | |
| Inventories | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Other Current Assets | 56.322 M | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Short Term Investments | 56.322 M | 560.219 M | 537.619 M | 412.333 M | 376.867 M | 303.479 M | 317.655 M | 294.420 M | |
| Total Receivables | 36.427 M | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Current Cash | 791.294 M | 130.849 M | 120.495 M | 189.182 M | 126.880 M | 156.172 M | 193.389 M | 155.464 M | |
| Total Non-current Assets | 375.546 M | 298.640 M | 333.355 M | 304.479 M | 271.669 M | 251.098 M | 205.030 M | 190.790 M | |
| Property Plant Equipment | 32.075 M | 30.273 M | 28.763 M | 27.381 M | 25.123 M | 22.806 M | 20.421 M | 17.671 M | |
| Other Assets | 70.957 M | 404.052 M | 433.686 M | 523.771 M | 409.648 M | 380.143 M | 322.913 M | 296.745 M | |
| Intangible Assets | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Goodwill | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Liabilities and shareholders’ equity | |||||||||
| Total Liabilities and shareholders’ equity | 1.260 B | 1.192 B | 1.173 B | 1.191 B | 986.163 M | 898.894 M | 925.275 M | 842.127 M | |
| Total liabilities | 223.452 M | 220.474 M | 210.736 M | 319.059 M | 206.244 M | 183.639 M | 176.853 M | 170.733 M | |
| Total current liabilities | 97.912 M | 105.090 M | 105.683 M | 110.851 M | 112.593 M | 95.499 M | 93.726 M | 103.884 M | |
| Accounts Payable | 13.689 M | 18.816 M | 13.145 M | 14.589 M | 12.364 M | 9.802 M | 13.260 M | 20.252 M | |
| Other liabilities | 33.440 M | 87.332 M | 82.446 M | 189.952 M | 80.490 M | 75.601 M | 70.588 M | 66.849 M | |
| Current long term debt | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Long term debt | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Other liabilities | 33.440 M | 87.332 M | 82.446 M | 189.952 M | 80.490 M | 75.601 M | 70.588 M | 66.849 M | |
| Minority interest | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Total Shareholder equity | 1.036 B | 971.062 M | 962.615 M | 871.956 M | 779.919 M | 715.255 M | 748.422 M | 671.394 M | |
| Common stock | 95.502 M | 2.885 B | 3.008 B | 3.049 B | 3.071 B | 3.108 B | 3.242 B | 3.260 B | |
| Retained earnings | -1.766 B | -1.913 B | -2.049 B | -2.177 B | -2.292 B | -2.393 B | -2.494 B | -2.590 B |